Veytics Intelligence
2026-11-13 · NASDAQ

Equillium Q3 Loss Widens On Higher R&D Expenses

Bản dịch chưa sẵn sàng. Đang hiển thị bài viết gốc.

(RTTNews) - Equillium, Inc., (EQ), a clinical-stage biotechnology company, reported a wider loss in its third quarter compared to last year, mainly due to higher research & development expenses.

Doc ban tin day du cua Veytics

Chung toi hien cong khai y chinh. Tao tai khoan mien phi de doc toan bo bai viet, luu, thao luan va ket noi voi boi canh thi truong va OSINT.